ASIT biotech (ASIT - BE0974289218),a Belgian clinical-stage biopharmaceutical company specialized in immunotherapy products for the treatment of allergies, is publishing a new article in the prestigious science journal ALLERGY.

ALLERGY is the official journal of the European Academy of Allergy and Clinical Immunology (EAACI). Its task is to promote links between fundamental research and clinical research in the fields of allergies and immunology. ALLERGY only publishes articles that are approved by a committee of renowned and independent scientific experts. The selection criteria for articles published in this review are the quality and originality of the scientific results presented.

This new article presents the results of the clinical trial for determining the maximum tolerated dose (Phase IIa) of the candidate product gp-ASIT+™ for the immunotherapy treatment of grass pollen-induced rhinitis. These are the results of the first clinical trial which showed that a short treatment with gp-ASIT+™ (4 medical visits over 3 weeks) reduced reactivity to an allergen challenge test and induced the production of antibodies capable of blocking the allergic reaction.

ASIT biotech has already published the results of the phase I/II clinical trial with gp-ASIT+™ in the Journal of Allergy and Clinical Immunology (JACI) and the results of the phase IIb clinical trial in the journal ALLERGY. This third publication in a prestigious science journal cASIT biotech (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company specialized in immunotherapy products for the treatment of allergies, is publishing a new article in the prestigious science journal ALLERGY.

ALLERGY is the official journal of the European Academy of Allergy and Clinical Immunology (EAACI). Its task is to promote links between fundamental research and clinical research in the fields of allergies and immunology. ALLERGY only publishes articles that are approved by a committee of renowned and independent scientific experts. The selection criteria for articles published in this review are the quality and originality of the scientific results presented.

This new article presents the results of the clinical trial for determining the maximum tolerated dose (Phase IIa) of the candidate product gp-ASIT+™ for the immunotherapy treatment of grass pollen-induced rhinitis. These are the results of the first clinical trial which showed that a short treatment with gp-ASIT+™ (4 medical visits over 3 weeks) reduced reactivity to an allergen challenge test and induced the production of antibodies capable of blocking the allergic reaction.

ASIT biotech has already published the results of the phase I/II clinical trial with gp-ASIT+™ in the Journal of Allergy and Clinical Immunology (JACI) and the results of the phase IIb clinical trial in the journal ALLERGY. This third publication in a prestigious science journal confirms the originality, quality and robustness of the clinical results obtained by ASIT biotech.

Thierry Legon, CEO of ASIT biotech, commented: “This new publication in ALLERGY will once more draw the attention of the global community of allergists to the remarkable properties of our flagship product, gp-ASIT+™.  These results have demonstrated for the first time in the world that allergen peptides allow allergic patients to be desensitised in only 3 weeks while other products require several months or even years to reach the same effect. These results have subsequently been confirmed throughout gp-ASIT+™’s clinical development up to Phase III which has demonstrated a convincing reduction in the combined score of symptoms and medication intake during natural exposure to grass pollens.”onfirms the originality, quality and robustness of the clinical results obtained by ASIT biotech.

Thierry Legon, CEO of ASIT biotech, commented: “This new publication in ALLERGY will once more draw the attention of the global community of allergists to the remarkable properties of our flagship product, gp-ASIT+™.  These results have demonstrated for the first time in the world that allergen peptides allow allergic patients to be desensitised in only 3 weeks while other products require several months or even years to reach the same effect. These results have subsequently been confirmed throughout gp-ASIT+™’s clinical development up to Phase III which has demonstrated a convincing reduction in the combined score of symptoms and medication intake during natural exposure to grass pollens.”

more about ASIT biotech